PCBs as Environmental Estrogens: Turtle Sex Determination as a Biomarker of Environmental Contamination

Judith M. Bergeron,† David Crews,† and John A. McLachlan‡

†Department of Zoology, Institute of Reproductive Biology, University of Texas at Austin, Austin, TX 78712 USA; ‡National Institute of Environmental Health Sciences, Research Triangle Park, NC 27709 USA

Polychlorinated biphenyls (PCBs) are widespread, low-level environmental pollutants associated with adverse health effects such as immune suppression and teratogenicity. There is increasing evidence that some PCB compounds are capable of disrupting reproductive and endocrine function in fish, birds, and mammals, including humans, particularly during development. Research on the mechanism through which these compounds act to alter reproductive function indicates estrogenic activity, whereby the compounds may be altering sexual differentiation. Here we demonstrate the estrogenic effect of some PCBs by reversing gonadal sex in a reptile species that exhibits temperature-dependent sex determination. Key words: biomarker, environmental estrogens, gonadal sex, PCBs, sexual differentiation, temperature-dependent sex determination. Environ Health Perspect 102:780–781 (1994)

Many polychlorinated biphenyls (PCBs) are industrialized chemicals such as those used in adhesives, fire retardants, and waxes (1). As a function of physical and chemical properties such as lipid solubility and low rate of degradation, PCBs persist in the environment; thus, individuals in industrialized nations are exposed to high levels of these compounds (2,3). Because chemicals of this nature tend to bioaccumulate, for instance, within food chains, they eventually reach measurable levels in human tissues or in nutrient systems such as placental cord blood, breast milk, and egg yolks. This may result in an individual being exposed to high levels during development, a time when toxic effects may be more detrimental than those seen in adults (3,4).

Reproductive disorders resulting from exposure to xenobiotic estrogens may include reductions in fertility, lower hatch rates in fish and birds, and decreased viability of offspring, as well as alterations in hormone levels or adult sexual behaviors, all of which have further implications, particularly in wildlife population dynamics (3–5). In addition, there is increasing suspicion that effects of estrogenic compounds are correlated to disorders of the male reproductive system, including increased occurrence of prostate and testicular cancers (6,7). There is a need for a sensitive bioassay with which the developmental effects of environmental estrogens can be determined. Reptiles with temperature-dependent sex determination (TSD), in which the incubation temperature of the egg determines the sex of the individual, may provide such a bioassay. Evidence of PCBs acting as estrogens in a TSD species may contribute to a clearer understanding of how estrogens may lead to reproductive dysfunction.

The red-eared slider turtle, Trachemys scripta, is a species that possesses a TSD pattern in which warm incubation temperatures, (e.g., 31 °C) produce all female hatchlings, whereas cooler incubation temperatures (e.g., 26 °C) produce all male hatchlings; intermediate temperatures (between 29.0 and 30.0 °C) result in varying ratios of males and females (8,9). In reptiles with TSD, the actions of estrogen mimic those of temperature with regard to gonadal differentiation (10,11). In the red-eared slider, as in many other TSD species, exogenous estrogens applied to the eggshell during the period of sexual differentiation can counteract the effects of male-producing temperatures and induce ovarian development (12–15).

Materials and Methods

Eggs for these experiments were purchased from Robert Kliebert (Hammond, Louisiana) and incubated on a layer of vermiculite: water (1:1) in temperature-controlled chambers (27.8 or 26.0 °C). We monitored embryonic development by candling eggs during early stages, then by dissecting a small sample of eggs approximately twice a week to determine specific developmental stages. At the beginning of the period of gonadal differentiation (stage 17: approximately 4 weeks from the date eggs are laid), which coincides with the developmental stage at which the embryos are sensitive to the effects of exogenous estradiol (10,11), eggs were randomly assigned to treatment groups and spotted with either PCB compounds (Ultra Scientific, Hope, Rhode Island) in 95% ethanol, estradiol-17β (Sigma, St. Louis, Missouri) in ethanol as a positive (hormone) control, or with ethanol alone as a negative (temperature) control. Incubation was continued at the experimental temperatures until hatch (approximately 7 more weeks at this temperature), at which time we dissected the hatchlings to determine resulting sex ratios. We determined gonadal sex and status of genital ducts by visualization under a dissecting microscope and verified sex histologically, as described previously for this species (8,9). In all cases that the gonad was female, the oviducts or Müllerian ducts were present. In some cases in which testes developed, the Müllerian ducts were also present, indicating estrogenic activity.

Results and Discussion

In the first experiment, 11 different PCB compounds believed to be estrogenic (16) were applied individually to eggs incubated at 27.8 °C. As shown in Table 1, each compound was administered at 2 doses, 15 eggs per dose. The eggs average 11.4 g (±0.21) each. Comparison of the resulting sex ratios showed that two compounds, 2,4′,6′-trichloro-4-biphenyl (compound F) and 2,3,4′,5′-tetrachloro-4-biphenyl (compound G), significantly reversed sex at a male-producing temperature (Fisher's Exact Test, p < 0.001). The former compound showed 100% sex reversal at 100 µg, or just below 9 ppm. In tests using mouse tissue, these same two compounds showed an appreciable affinity for estrogen receptor, due in part to their conformational properties as hydroxybiphenyls (16,17). As metabolites of other PCBs, hydroxylated PCBs such as F and G may exist in steady-state concentrations in aquatic environments, potentially exposing wildlife to their effects via direct contact or through the food chain (17).

Because purified PCB compounds are rarely found in the environment, we decided in the second series of experiments to look at combinations of the same PCBs. All eggs were incubated at 27.8 °C and received a low (10 µg), medium (100 µg), or high (145–190 µg) dose of compounds in ethanol. Some eggs received a cocktail of all PCBs except the two that caused sex reversal (F and G). Others were exposed to combined hydroxybiphenyls, excluding F and G. Lastly, some eggs were spotted with combined nonhydroxylated PCBs. In all three conditions, there was no evidence of sex reversal.

Address correspondence to J. M. Bergeron, Department of Zoology, Institute of Reproductive Biology, University of Texas at Austin, Austin, TX 78712 USA.

We acknowledge the technical assistance of A. Alexander, T. Cole, H. Nguyen, and J. O'Brien, and J. Branch for graphics. This research was supported by a National Science Foundation postdoctoral fellowship to J.M.B. and National Institute of Mental Health Research Scientist Award 00135 to D.C.

Received 10 March 1994; accepted 27 June 1994.
Table 1. Effects of some PCB compounds on sex determination

<table>
<thead>
<tr>
<th>Compound</th>
<th>% Hatchlings with female gonads (low dose/high dose)</th>
<th>% Hatchlings with oviducts (low dose/high dose)</th>
</tr>
</thead>
<tbody>
<tr>
<td>A 2',5'-dichloro-3-biphenylo</td>
<td>0/0</td>
<td>0/14</td>
</tr>
<tr>
<td>B 2',2',4-trichlorobiphenyl ether</td>
<td>7/0</td>
<td>21/0</td>
</tr>
<tr>
<td>C 2',2',5'-trichloro-4-biphenylo</td>
<td>0/0</td>
<td>7/0</td>
</tr>
<tr>
<td>D 2',3',4'-trichlorobiphenyl</td>
<td>7/0</td>
<td>7/8</td>
</tr>
<tr>
<td>E 2',5'-trichlorobiphenyl</td>
<td>0/0</td>
<td>0/0</td>
</tr>
<tr>
<td>F 2',3',4',5'-tetrachloro-4-biphenylo</td>
<td>0/100</td>
<td>0/100</td>
</tr>
<tr>
<td>G 2',3',4',5'-tetrachlorobiphenyl</td>
<td>4/50</td>
<td>8/71</td>
</tr>
<tr>
<td>H 2',4',5'-tetrachlorobiphenyl ether</td>
<td>0/0</td>
<td>0/0</td>
</tr>
<tr>
<td>J 2',4',4'-tetrachlorobiphenyl</td>
<td>0/0</td>
<td>0/0</td>
</tr>
<tr>
<td>K 2',4',4'-tetrachloro-3,5-pentachloro-2-biphenyl</td>
<td>0/0</td>
<td>0/0</td>
</tr>
<tr>
<td>L 2',3',4',5'-pentachloro-2-biphenyl</td>
<td>100</td>
<td>100</td>
</tr>
</tbody>
</table>

Eleven compounds were applied to eggs incubated at 27.8°C in two doses per compound. The doses were: A, 10, 10; B, 10, 10; C, 0, 0; D, 5, 0; E = 25, 25; G = 3.5, 3.5; H = 10, 10; I = 10, 10; J = 10, 10; K = 10, 10; L = 10, 10. The estradiol control consisted of 10 μg estradiol-17β.

Figure 1. Percentage of female hatchlings at a temperature that normally produces 100% males (26°C) after treatment with two estrogenic PCB compounds in ethanol. Controls: temperature, ethanol alone; hormone, 10 μg estradiol-17β. PCB compounds: F, 2',4',5'-trichloro-4-biphenyl; G, 2',3',4',5'-tetrachloro-4-biphenyl. Sample sizes in parentheses. Significant sex reversal is indicated by *p < 0.05; **p < 0.005; ***p < 0.001.

Because we knew compounds F and G showed estrogenic activity at the slightly higher temperature, we decided to test these two compounds at a temperature that produces 100% males (26°C). Both compounds showed significant sex reversal at this temperature (Fig. 1). When combined, F and G synergized, resulting in a significant increase in ovarian development at a dose of 10 μg, or less than 1 ppm (Fisher's Exact Test, p < 0.01), whereas F alone and G alone required at least a 10-fold higher dose to show sex reversal. Exogenous estradiol-17β produces similar results at a dose of 0.5 μg, or 0.4 ppm (5). As with the earlier experiments involving compounds F and G, whenever the gonad was feminized, the oviducts were retained, and in some cases where testes developed, there were also Müllerian ducts present.

The nature of TSD in this and other reptile species provides a useful system in which to assay the extent of estrogenic activity found in xenobiotic compounds. This report contributes laboratory evidence of the effect of PCBs on sex determination, emphasizing the usefulness of a TSD species as a biomarker to assess environmental contamination and serve as a warning of conditions threatening wildlife populations. The PCB levels reported here as effective in disrupting normal gonadal differentiation in the turtles are comparable to average levels of PCBs found in human breast milk in industrialized nations (3). In addition, this study supports the contention that environmental estrogens, through their action on reproductive development, have the potential to alter wildlife populations as well as contribute to reproductive dysfunction in humans (3–7). Future studies investigating the mechanisms through which these estrogenic compounds act to affect sex differentiation will continue to shed light on a human contribution to the environment.

REFERENCES

Estrogenicity of Environmental PCBs

The paper by Bergeron, Crews, and McLachlan, "PCBs as Environmental Estrogens: Turtle Sex Determination as a Biomarker of Environmental Contamination" (EHP 102:780-781) presents data on the estrogenic activity of 11 chlorinated biphenyls or diphenyl ethers, or hydroxylated derivatives thereof, selected so as to represent a variety of structural types. Some of the PCB types examined (e.g., compounds A, C, D, E, and J) arise from PCB congeners actually detectable in the commercial Aroclors (1) and hence also in environmental samples, whereas other PCB types (e.g., those with heavily uneven chlorination of the two rings, as in compound F,G, and L) arise from PCB congeners that are not detectable in either the Aroclors themselves (1) or even environmentally transformed PCB compositions (2). It is noteworthy that the only compounds found to have statistically significant estrogenic activity (compounds F and G) both represented 4-hydroxylation products of PCB congeners belonging to the nonenvironmental group, whereas the five compounds representative of PCB structures actually present in the environment were all negative. In short, the results present zero evidence that environmental PCBs present risk of estrogenic activity.

This is hardly what the authors claim, however. In their discussion they state (p. 781):

“This report contributes laboratory evidence of the effect of PCBs on sex determination... and serves as a warning of conditions threatening wildlife populations. The PCB levels reported here as effective in disrupting normal gonadal differentiation in the turtles are comparable to average levels of PCBs found in human breast milk in industrialized nations.”

This misleading statement represents a false alarm that can only impede the search for the environmental contaminants that actually do present estrogenic risk.

Stephen B. Hamilton
Environmental Programs
GE Company
Fairfield, Connecticut

REFERENCES


Response to Hamilton

There are several points we would like to address in our response. First of all, the compounds studied were chosen because these particular congeners were believed to be estrogenic based on their conformational structure. The primary reason for conducting this type of study was to show the effectiveness of a temperature-dependent sex determination (TSD) species as a tool in assessing estrogenic activity in vivo. This point is furthered by an earlier report in EHP by Guillette et al. (1). While the PCB compounds we used may not be primary components of commercially available PCB mixtures, there are parallels between these compounds and other PCB congeners in the pattern of ortho-chlorination substitutions, as Korach et al. (2) indicate. It is important to study how these structures affect a developing organism in order to understand how PCBs can act as estrogens. Though these particular congeners may not be used in the readily available mixtures, McKinney et al. (3) make reference to goals of using PCBs that are easily detoxified via hydroxylation. If such considerations lead to composition of commercially available PCB mixtures away from congeners that exhibit a dioxinlike toxicity, these considerations should include assessment of the estrogenic activity of these compounds. The TSD system can be used to test such mixtures in vivo. Furthermore, the appearance of hydroxylated PCB congeners in "nature" is an emerging issue: for example, Bergmeyer et al. (4) report that the hydroxylated forms of heavily chlorinated (penta- or heptachlorinated) biphenyls were among the most sensitive forms of PCBs found in blood from humans or seals. Clearly, this class of molecules may have environmental significance which is only now being appreciated.

The second point that we would like to emphasize regards the potential for second-generation exposure to PCBs as environmental estrogens. While the congeners that we found to clearly exhibit estrogenic activity may not be produced in the commercial PCB mixtures, or even found in soil and water samples, they may exist within animal tissues during metabolism of the environmental compounds. Maternal metabolic by-products may affect the reproductive system at a critical stage in development of the offspring, producing the detrimental estrogenic effect on the second generation. This is particularly a concern when enhanced estrogenic effects are produced by the synergy of different combinations of low-level PCBs, an issue brought to light by the study in question.

Finally, we share Dr. Hamilton’s concern that false alarms may impede identification of contaminants that actually present risk of estrogenic activity. However, Dr. Hamilton’s cited quotation of our discussion, and his interpretation of it, requires clarification so as not to be misleading. Dr. Hamilton’s abbreviated quote would lead readers to believe that it is our report which we say serves as a warning of threatening environmental conditions. In fact, the passage he omitted clearly identifies “the usefulness of a TSD species as a biomarker” to serve in the capacity which Dr. Hamilton apparently ascribes to our report.

Our findings support the call from the scientific community for the need to further study the mechanisms of estrogenic activity of environmental contaminants. These findings, together with the growing body of evidence that a number of environmental compounds mimic estrogens and do have an effect on developing reproductive systems, provide ample indication for further investigation of these mechanisms and their outcomes. Our report suggests a model by which to continue these efforts, and we appreciate the continued interest in our work and the opportunity to address questions regarding it.

Judith Bergeron
David Crews
Institute of Reproductive Biology
University of Texas at Austin

John A. McLachlan
NIEHS
Research Triangle Park, North Carolina

REFERENCES
2. Korach KS, Saaver P, Chai K, McLachlan JA, McKinney JC. Estrogen receptor-binding activity of polychlorinated hydroxyphenyl-
Human Toxicity of PBDDs and PBDFs

The brilliant literature review and health risk assessment by Menneer and Cheng-Chung, "Polychlorinated Dibenzo-p-dioxins and Dibenzofurans: Literature Review and Health Assessment" [EPH 102(suppl 1):265-274], states that "reports of human toxicity associated with exposure to PBDDs and PBDFs were not found" (p. 272). In fact, in their review, no references are discussed or quoted regarding human studies.

Two papers have been published on the human toxicology of these compounds. The first (1) is a recent report, previously presented at the Dioxin 90 Congress (2), about a chemist who was exposed to 2,3,7,8-tetrabromodibenzodioxin (TBBDD) and to 2,3,7,8-tetrachlorodibenzodioxin (TCDD) in March and September 1996, respectively, when synthesizing these chemicals. The chemist was described as "in good health" in 1990, when determinations of chlorinated and brominated dioxins and dibenzofurans were performed on whole blood. High concentrations of several congeners were detected, and the results were used to discuss the half-life of the chemicals in humans. The subject presented a mild chloracne after an unspecified time from his exposure to bromodioxins in March, suggesting that TBBDD could produce skin effects as chlorodioxin. Other more relevant symptoms occurred after the exposure to TCDD in September, and the patient was hospitalized for a short period.

The second was a study of subjects exposed to PBDDs and PBDFs as a result of working at a BASF factory in etiunon blending of polybutyltetraethylphthalate with decabromodiphenyl ether, used as a flame retardant. The intensity of exposure was determined in 1989 through air monitoring (3). The paper presents blood levels of 2,3,7,8,5'-TBDDF and TBBDD and of total congener profiles for some exposed workers and the results of a comparison of several immunological tests in a population of exposed versus a population of unexposed deriving from the same working cohort. Workers had detectable blood levels of TBBDD and TBBDF; half-life estimates of these chemicals are presented. The results of immunological tests were described as "not adversely impacted at these burdens of PBDDs and PBDFs," even though the results of several tests showed a correlation with exposure, and in the subject having the highest blood levels of PBDDs and PBDFs, immunological changes were quite relevant. The authors stated that clinical examination did not reveal "skin lesions consistent with an acnegenic response."

It should be stressed that the results of the two quoted articles do not change the conclusions of Menneer and Cheng-Chung on the health risks of PBDDs and PBDFs. However, slightly different suggestions for future research can be derived. Human populations have been or are exposed to these chemicals because of their use in several work processes involving flame retardants, environmental exposures (mainly due to municipal incinerators), or because of accidents due to thermal decomposition of flame retardants. These exposed human populations can be suitable, at least in theory, for toxicological and epidemiological observations.

Enzo Merler
Eva Buiatti
Centre for the Study and Prevention of Cancer Florence, Italy

REFERENCES


Arsenic Risk Assessment

A commentary highly critical of two of our published studies was recently published in Environmental Health Perspectives (Carlson-Lynch et al., 102:354-356). One of our papers examines the epidemiological evidence for a methylation threshold for inorganic arsenic and concludes that there is no consistent evidence to support the hypothesis of such a threshold in humans (4). The second paper critiqued by Carlson-Lynch et al. estimates the human cancer risks of arsenic at internal sites (lung, liver, kidney, and bladder) using linear extrapolation from Taiwanese data (2). Carlson-Lynch et al. contend that the analyses conducted in our studies are flawed and that the conclusions reached in our publications are erroneous, rendering them unacceptable for use by the EPA in risk assessment.

Whether or not our studies are used by the EPA for risk assessment is of little concern to us, but we are certainly concerned about statements that they are flawed. Careful examination will show that all of the major points raised in the commentary are either incorrect or have no valid basis. We would like to respond to the criticisms made, point by point, in the order presented, beginning with the methylation paper (1).

Critique: The average arsenic exposures in almost all of the studies analyzed were too low to observe methylation saturation.

Response: The commentators base this statement on three issues. First, the authors state that evidence from an experimental study (of only four human volunteers each receiving only one dose level) suggests that methylation would be completely saturated at exposures greater than 500 μg/day (3). However, at the highest oral dose in this study, 1000 μg/day, the amount of urinary arsenic in the inorganic form was only 26%, hardly demonstrating methylation saturation even at this level. Buceti et al. (3) state in their paper that "sorption of the arsenic metabolites in urine indicated that the arsenic methylation capacity of the human body was not yet saturated, even with an oral daily dose of 1000 μg As." The evidence of any metabolic saturation from this study is not conclusive. Each of four arsenic dosing levels was assigned to a different individual subject, making it impossible to differentiate interindividual differences in methylation efficiency from dose-dependent effects that might apply to a general population.

Second, the authors state that we analyzed only two groups with average urinary arsenic levels at or above 150 μg/l, which they hypothesize corresponds to the concentration above which methylation saturation occurs. This statement obscures the fact that 1) the two groups combined had a total of 35 people, 2) our analysis of available individual data (see Figure 2 of our paper) included 14 persons with urinary arsenic levels >190 μg/l. No trend of higher relative proportions of unmethylated arsenic is suggested for those 14 individuals.

Third, the authors state: "...a regression analysis on the individual data within the Yamauchi et al. [4] population was borderline significant at p = 0.10..." (p. 354). However, this was just one of nine regression analyses we presented. The slopes were positive in four (including the Yamauchi study) but negative in five (i.e., Table 9).

As a matter of interest, in our more recent studies of chronically exposed popu-